menu
    • menu
    [{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"4D Molecular Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Preclinical","graph3":"Arbor Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies \/ Arbor Biotechnologies, Inc","highestDevelopmentStatusID":"4","companyTruncated":"Arbor Biotechnologies \/ Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"ABO-101","moa":"GOX","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies","amount2":2.1200000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":2.1200000000000001,"dosageForm":"Infusion","sponsorNew":"Arbor Biotechnologies \/ Chiesi Group","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies \/ Chiesi Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Arbor Biotechnologies

    Menu

    Arbor Biotechnologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arbor Biotechnologies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arbor Biotechnologies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABO-101

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Chiesi Group

                            Deal Size : $2,115.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership

                            Details : Under the terms of the transaction, Chiesi will receive exclusive rights to develop and commercialize ABO-101 for primary hyperoxaluria type 1 (PH1).

                            Product Name : ABO-101

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $115.0 million

                            October 06, 2025

                            Lead Product(s) : ABO-101

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Chiesi Group

                            Deal Size : $2,115.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arbor Biotechnologies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Arbor Biotechnologies

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : 4D Molecular Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            4DMT And Arbor Partner To Co-Develop Next-Gen Genetic Medicines For CNS Diseases

                            Details : 4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates for central nervous system diseases, including amyotrophic lateral sclerosis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 03, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : 4D Molecular Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth